RxDoctor Payments Data

William Long, MD

Family Medicine · Charlotte, NCNPI 1992778906

Payments from drug & device makers

$65,676in general payments, 2019–2025

Across 785 payments — averaging $83.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$49K
  • Intuity Medical Inc$3K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$997
  • Intuitive Surgical$980
  • plus $9K from 54 others

What the payments were for

  • Consulting fees$18,00027%
  • Speaking & faculty fees$27,31642%
  • Travel & lodging$6,32610%
  • Food & beverage$14,02821%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neurocrine Biosciences, Inc.63$49,282
Intuity Medical Inc4$3,014
Novo Nordisk59$1,090
Lilly USA, LLC59$1,050
AstraZeneca49$997
Intuitive Surgical5$980
Bausch Health US, LLC41$733
Novartis40$692
Bayer41$581
Sunovion Pharmaceuticals Inc.35$567
Johnson & Johnson30$449
Amgen(2 entities)23$394
Kowa Pharmaceuticals America, Inc.31$387
Boehringer Ingelheim21$371
Esperion Therapeutics, Inc.25$362
Eisai Inc.17$354
Pfizer18$332
Otsuka America Pharmaceutical, Inc.11$315
Amarin Pharma, Inc.26$312
Idorsia Pharmaceuticals US Inc12$289
Avanir Pharmaceuticals, Inc.25$282
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$211
Exact Sciences10$185
Astellas Pharma US Inc12$182
Collegium Pharmaceutical, Inc.7$150
Abbott7$148
Forte Bio-pharma LLC7$129
AbbVie(2 entities)7$109
Arbor Pharmaceuticals, Inc.6$107
Merz North America, Inc.1$104
Azurity Pharmaceuticals, Inc.4$98
Convatec Inc.4$94
Teva Pharmaceuticals USA, Inc.4$92
Sanofi-aventis U.S. LLC4$87
GSK5$82
Alkermes, Inc.5$76
Argenx US, Inc.3$72
Ardelyx, Inc.4$63
Jazz Pharmaceuticals Inc.4$60
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$59
Merck3$56
Sumitomo Pharma America, Inc.3$56
CMP Pharma, Inc.3$55
Otsuka Pharmaceutical Development & Commercialization, Inc.2$47
Urovant Sciences Inc2$45
TMS Neurohealth Centers Inc.2$38
Viatris Specialty LLC1$35
Indivior Inc.2$35
Daiichi Sankyo Inc.2$35
Tolmar, Inc.2$34
Zimmer Biomet1$29
Phathom Pharmaceuticals, Inc.1$27
Biogen1$22
Alnylam Pharmaceuticals Inc.1$20
Medtronic1$19
C2n Diagnostics, LLC1$19
Inspire Medical Systems, Inc.1$18
Gilead1$17
Vertex1$17
Electromed, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,676 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$246,995
Medicare patients
489
Services billed
4,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban569$211,712
EnbrelEtanercept14$110,289
JardianceEmpagliflozin192$104,807
OzempicSemaglutide104$104,651
TrulicityDulaglutide93$90,696
BiktarvyBictegrav/Emtricit/Tenofov Ala18$71,074
XareltoRivaroxaban125$69,776
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$60,175
LinzessLinaclotide101$53,589
MounjaroTirzepatide40$42,806
NuedextaDextromethorphan Hbr/Quinidine28$38,973
FarxigaDapagliflozin Propanediol74$38,191
EntrestoSacubitril/Valsartan58$31,973
MyrbetriqMirabegron88$29,396
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$27,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$332$223,963608 claims
Lilly USA, LLCTrulicity, Mounjaro$1,050$133,502133 claims
Boehringer IngelheimJardiance, Tradjenta$371$116,314216 claims
AmgenEnbrel$394$110,28914 claims
Novo NordiskOzempic$1,090$104,651104 claims
Johnson & JohnsonXarelto, Risperdal Consta$449$82,187144 claims
GileadBiktarvy$17$71,07418 claims
AbbVieLinzess$109$53,589101 claims
Avanir Pharmaceuticals, Inc.Nuedexta$282$38,97328 claims
AstraZenecaFarxiga$997$38,19174 claims
GSKTrelegy Ellipta, Breo Ellipta$82$36,72272 claims
NovartisEntresto$692$31,97358 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →